Back to list
Celiac Disease - 246138
Study Dates: TBD - TBD
Study Number
246138
Group
● Celiac Disease
Compensation
Up to: $2,100
Gender
Male, Female
Age
18-70
Additional Information
Screening Start: July 2020
Details
The purpose of this study is to assess the safety, tolerability, and activity of an investigational medication (KAN-101) in patients with Celiac Disease on a gluten-free diet.
To take part, you will be required to come to our research clinic for an initial screening visit. If you qualify you will be required to stay in-house for 4 days/ 3 night(s) and return for 3 follow up visits.